Cost Comparison of Parenteral Estrogen and Conventional Hormonal Treatment in Patients With Prostatic Cancer

  title={Cost Comparison of Parenteral Estrogen and Conventional Hormonal Treatment in Patients With Prostatic Cancer},
  author={Peter Henriksson and Reinhard Stege},
  journal={International Journal of Technology Assessment in Health Care},
  pages={220 - 226}
  • P. HenrikssonR. Stege
  • Published 1 March 1991
  • Medicine, Biology
  • International Journal of Technology Assessment in Health Care
Abstract The present study compares the cost of antitumor therapy and adverse cardiovascular effects during the first year of treatment with oral estrogens, nonoral estrogens, or surgical castration in patients with prostatic cancer. We found a much higher cost for patients treated with orchidectomy and oral estrogens than for patients treated with nonoral estrogens. Twenty-five percent of the patients treated with oral estrogen suffered cardiovascular complications, compared to none of the… 

Comparison of the Cost-Effectiveness of Various Therapies for Common Prostatic Disorders

The magnitude of these diseases, therapies available and relevant cost-effectiveness studies are reviewed, and each therapeutic method has its advocates, and overall survival rates are similar for all treatments.

Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen

The present pilot study tested the clinical performance of a new pharmacokinetically guided dosing regimen of parenteral estrogen in patients with advanced prostatic carcinoma. The aim was to

High dose rate brachytherapy boost for localized prostate cancer Clinical and patient-reported outcomes

Combined RT provides high cure rates, but entails a risk of side effects of which most seem to be of limited duration, possibly suggesting “response shift” effects.

Clinical and Economics Conditions in the Treatment of Prostate Cancer

In an attempt to improve the results obtained with endocrine treatment, the concept of combining surgical or medical castration with antiandrogens was introduced and could offer improved response rates and survival in a significant number of patients.

Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer.

Investigation of quality of life, sex-role identity, and sexual function in 15 patients with stage D prostate cancer, before and after surgery found orchidectomy did not appear to affect quality ofLife, or sex- role identity, however, loss of sexual function did present as an area of concern.

Radiotherapy in prostate cancer : information, quality of life and prostate volume

S satisfaction with information in prostate cancer patients treated with surgery and salvage radiotherapy compared to patients with curative radiotherapy alone is less, despite similar health related quality of life, and there is room for improvement.

Geographic Variation in the Treatment of Prostate Cancer in Connecticut

  • A. Polednak
  • Medicine
    International Journal of Technology Assessment in Health Care
  • 1993
Abstract In Connecticut there was considerable variation by town of residence in the proportions of patients diagnosed in 1985–1988 receiving transurethral resection only, prostatectomy, and

Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in connecticut

This study presents data on stage‐specific prostate cancer incidence rates in United States black patients versus white patients, and there are no data comparing treatment received by black versuswhite patients with prostate cancer.

Sensitivity Analysis in Health Economic and Pharmacoeconomic Studies

Improvement is required in the extent of reporting of sensitivity analyses in the health economics despite the fact that all published pharmacoeconomic guidelines suggest the use of sensitivity analysis.

Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

Evaluated the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease to address weaknesses in understanding of the economic consequences of therapies for prostate cancer.



Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

The 1.0-mg dose has been as effective as the 5.0‐mg dose in controlling the prostate cancer, but it does not seem to be associated with the excess risk of cardiovascular death.

Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.

Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment.

Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate

Patients with cancer of the prostate treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections have responded to therapy and there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months.

Single‐drug parenteral estrogen treatment in prostatic cancer: A study of two maintenance‐dose regimens

Treatment of 17 patients with prostatic cancer with 320 mg polyestradiol phosphate (PEP) as intramuscular injections every fourth week suppressed serum testosterone (T) values to orchidectomy levels

Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.

Parenteral administration of oestrogen caused a less marked change in the coagulation system than oral administration and should be the treatment of choice for prostatic carcinoma.

Estrogen therapy and liver function—metabolic effects of oral and parenteral administration

Oral estrogen therapy for prostatic cancer is clinically effective but also accompanied by severe cardiovascular side effects, and the impact of exogenous estrogens on the liver is dependent on the route of administration and the type and dose of estrogen.


Evidence is presented that significant improvement often occurs in the clinical condition of patients with far advanced cancer of the prostate after they have been subjected to castration and this work provides a new concept of prostatic carcinoma.

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate

It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.

Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer

Patients with prostatic cancer during long-term oestrogen treatment were found to have increased levels of factor VII, factor VIII:C and fibrinogen, and patients showed increased formation of thromboxane, which imply a hypercoaguable state and platelet activation.